Approved HIV Drugs
Approved HIV Drugs
HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk
- Details
- Category: Approved HIV Drugs
- Published on Friday, 28 October 2016 00:00
- Written by Keith Alcorn
Insomnia, dizziness, headache, and other central nervous system (CNS) side effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur among women, people over age 60, and people starting abacavir at the same time, a German research group reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week.
Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 03 May 2016 00:00
- Written by Liz Highleyman
The Genvoya single-tablet regimen containing tenofovir alafenamide (TAF) suppressed HIV as well as a similar coformulation containing the older tenofovir disoproxil fumarate (TDF), but demonstrated better bone and kidney tolerability after 2 years of treatment, according to a report in the May 1 edition of the Journal of Acquired Immune Deficiency Syndromes.
6. New TAF Version of Tenofovir Approved in Combo Pill
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 30 December 2015 00:00
- Written by Liz Highleyman
In November the U.S. Food and Drug Administration announced the approval of Gilead Sciences' Genvoya, a new single-tablet regimen containing the integrase inhibitor elvitegravir, the booster cobicistat, emtricitabine, and tenofovir alafenamide or TAF -- a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate (TDF).
Tenofovir Resistance May Develop in More than Half of Patients Failing Treatment
- Details
- Category: Approved HIV Drugs
- Published on Friday, 05 February 2016 00:00
- Written by Gus Cairns
More than half of people who experienced failure of a tenofovir-based antiretroviral regimen in sub-Saharan Africa had resistance to tenofovir, a meta-analysis of drug resistance studies published in the January 28 online edition of Lancet Infectious Diseases has shown. The study found that the prevalence of tenofovir resistance after first-line treatment failure ranged from 20% in Western Europe and North America to 56%-60% in sub-Saharan Africa.
EACS 2015: Dual Therapy with Protease Inhibitors and Lamivudine Suppresses HIV
- Details
- Category: Approved HIV Drugs
- Published on Monday, 23 November 2015 00:00
- Written by Liz Highleyman
Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.
More Articles...
- EACS 2015: Can Dolutegravir Dual Therapy or Monotherapy Keep HIV Suppressed?
- IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART
- IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV
- CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?
Web Design and Development by